Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After a slow first half, merger and acquisition deals are heating up for the remainder of 2022. In the efforts to boost its presence in rare hematology, Pfizer recently announced it is acquiring Global Blood Therapeutics for $5.4B.

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease Patients Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease Patients

GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

Global Blood (GBT) Up 1.9% Since Last Earnings Report: Can It Continue?

Pfizer

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Global Blood Therapeutics, Inc. (GBT) (NasdaqGS: GBT) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of GBT will receive $68.50 in cash for each share of GBT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,

GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT

Atlas Air Worldwide

Avalara Inc

CyberOptics

NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atlas Air Worldwide Holdings, Inc. (NASDAQ: AAWW)'s  sale to funds managed by affiliates of Apollo Global Management, Inc. and affiliates of J.F. Lehman & Company and Hill City Capital for $102.50 per share in cash.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR

Apellis Pharma

Beam Therapeutics

Chemocentryx

Fate Therapeutics

Karuna Therapeutics Inc

Intellia Therapeutics

PTC Therapeutics

Repligen

Twist Bioscience Corp

Barron's screened for stocks such as Global Blood Therapeutics and Karuna Therapeutics that popped this summer.

10 Stocks Driving the Biotech Resurgence

Seacoast Banking Corporation of Florida

NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Global Blood Therapeutics, Inc. (NASDAQ: GBT)'s  sale to Pfizer Inc. for $68.50 per share in cash. If you are a Global Blood shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE, SBCF

Amgen

Merck

Seagen

SPDR S&P Pharmaceuticals ETF

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

Get ready for more merger mania in pharma sector the rest of the year

NEW YORK , Aug. 9, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Global Blood Therapeutics, Inc. (GBT), relating to its proposed acquisition by Pfizer Inc. Under the terms of the agreement, GBT shareholders are expected to receive $68.50 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/global-blood-therapeutics-inc.

Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Global Blood Therapeutics, Inc. - GBT

Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings

Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, Global Blood Therapeutics, for $5.4 billion, representing $68.50 per GBT share.

Pfizer is acquiring Global Blood Therapeutics

Wilmington, Delaware--(Newsfile Corp. - August 9, 2022) - Rigrodsky Law, P.A. is investigating Global Blood Therapeutics, Inc. ("Global Blood") (NASDAQ: GBT) regarding possible breaches of fiduciary duties and other violations of law related to Global Blood's agreement to be acquired by Pfizer Inc. Under the terms of the agreement, Global Blood's shareholders will receive $68.50 per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-global-blood-therapeutics-inc.To contact Seth D.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Global Blood Therapeutics, Inc. Buyout

Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue from its Covid-19 vaccine and treatment. Pfizer will pay US$68.50 per GBT share, which represents a 7.3% premium over Friday's closing price and nearly 43% over Thursday's closing price.

Pfizer to buy Global Blood Therapeutics for US$5.4bn

NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT), in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE). Under the terms of the merger agreement, the Company's shareholders will receive $68.50 in cash for each share of Global Blood common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.

The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.

Why Global Blood Therapeutics Stock Was Trouncing the Market Today

Source: ra2 studio/Shutterstock Last week, Global Blood Therapeutics (NASDAQ: GBT ) stock was thrust into the spotlight on reports of a potential buyout bid from Pfizer (NYSE: PFE ). Today, though, Pfizer has officially disclosed that it will buy the company for $5.4 billion.

GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Global Blood Therapeutics, Inc. (NASDAQ: GBT) to Pfizer Inc. for $68.50 per share in cash is fair to Global Blood shareholders. Halper Sadeh encourages Global Blood shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns

Global Blood (GBT) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Global Blood Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GBT

Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week. The post Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics appeared first on Investor's Business Daily.

Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics

Pfizer said it would pay $68.50 per share for Global Blood Therapeutics which sells a sickle cell disease treatment called Oxbryta

Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.

Pfizer Inc. (PFE) announced it is buying Global Blood Therapeutics (GBT) for $5.4 billion. This is why.

Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion

The New York drugmaker is buying Global Blood Therapeutics, which sells a drug for sickle-cell disease and has two in development. It will pay $68.50 per share.

Pfizer reaches $5.4B deal for Global Blood Therapeutics

Pfizer Inc. PFE, -1.18% has agreed to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the companies said Monday, confirming a report by the Wall Street Journal. Pfizer will pay $68.50 a share in cash for Global Blood Therapeutics, which has one of few approved treatments for sickle-cell disease, a painful inherited blood disorder that most affects people of African, Middle Eastern and South Asian descent.

Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment

Pfizer Inc said on Monday it has agreed to buy blood disorder drugmaker Global Blood Therapeutics in a $5.4 billion deal, as it looks to fortify its product pipeline.

Pfizer to buy Global Blood Therapeutics in $5.4 billion deal

NEW YORK & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). The acquisition complements and further enhances P

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

Pfizer Inc. PFE, -1.18% has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal reported, citing people familiar with the matter. The news comes after the Journal reported Friday that the two were in advanced talks.

News for Global Blood Therapeutics Stock (GBT)